On March 23, JumpCan Pharmaceutical and Pharmplus entered into a deep collaboration for the global Class 1 innovative drug Benvitimod Cream (Zelimei), marking its debut launch in Pharmplus's national chain pharmacies. As a non-hormonal dermatological new drug approved simultaneously...
Recently, the final review results of the Jiangsu Association of Chinese Medicine, the Jiangsu Association of Integrative Medicine, and the Jiangsu Association of Acupuncture-Moxibustion’s TCM Science and Technology Awards for 2024–2025 were publicized. The project "Key Technological Innovation...
JumpCan Pharmaceutical (stock code: 600566) recently announced it has formally signed a collaboration agreement with thederma, granting JumpCan Pharmaceutical exclusive commercialization rights for thederma's Benvitimod Cream (Zelimei) in the People's Republic of China (excluding...
Recently, the Center for Drug Reevaluation, NMPA and the National Center for ADR Monitoring, China issued a commendation to units with outstanding performance in 2025. JumpCan Pharmaceutical Group was awarded the title of "Outstanding Enterprise for Drug, Device and Cosmetic...
JumpCan Pharmaceutical (stock code: 600566) and Akeso (stock code: 9926.HK) have officially signed a collaboration agreement. JumpCan Pharmaceutical obtains exclusive commercialization rights for the Class 1 innovative drug Ebronucimab Injection (Yixining) in the People's Republic of China...
JumpCan Pharmaceutical Partners with PrimeGene to Accelerate Commercialization of Class 1 Innovative Drug Pumecitinib
JumpCan Pharmaceutical Group recently announced that it has entered into a collaboration agreement with PrimeGenX Therapeutics Co., Ltd. (hereinafter "PrimeGene") for the Class 1 innovative JAK1/2 inhibitor Pumecitinib (PG-011) Nasal Spray. Under the terms of the agreement, JumpCan...
JumpCan Pharmaceutical's New Drugs Selected for the First Batch of the Jiangsu Province Innovative Drug and Device Product Catalogue
Recently, the Industry and Information Technology Department of Jiangsu, in conjunction with the Jiangsu Provincial Department of Science and Technology, the Jiangsu Commission of Health, the Jiangsu Healthcare Security Administration, and the Jiangsu Medical Products Administration, released...
Fighting the Flu with a Single Dose — JumpCan's Innovative Anti-Influenza Drug Jikeshu Shines at the VAS Forum
From November 26 to 27, the "China Drugstore Business College VAS Forum" was grandly held in Guangdong Province. Co-organized by the Chain Pharmacy and Clinic Professional Committee of the All-China Federation of Industry and Commerce Medical & Pharmaceutical Industry Chamber, China...
The Class 1 Innovative Anti-influenza Drug, Jikeshu (Sebaloxavir Marboxil Tablets), was Launched on JD Health for the First Time
On October 13th, the innovative Class 1 anti-influenza drug Jikeshu (Sebaloxavir Marboxil Tablets), which only requires one dose of medication for the entire course of treatment, was launched online on the JD Health platform. JumpCan Pharmaceutical relies on JD Health's advantage of...
Three Products of JumpCan Pharmaceutical Honored as "China Drugstore Selected Brands"
From September 25th to 28th, the 2025 China Drugstore All Partners Show was grandly held. During the conference, several authoritative industry honor lists were announced, garnering widespread attention. JumpCan Pharmaceutical's Pudilan Xiaoyan Oral Liquid, Xiao'er Chiqiao Qingre Granules...